Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens

Anthony Oyekunle, MD FMCPath, Evgenii Shumilov, MD, Philippe Kostrewa, Andreas Burchert, MD, Patrick Wuchter, MD, Ulrike Bacher, MD, Gerald Wulf, MD, Nicolaus Kroeger, MD Prof

Blood (2016) 128 (22): 2176.

https://doi.org/10.1182/blood.V128.22.2176.2176

Published: 2016

Journal Articles

Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML

Roxana Schaab, Christina Ganster, PhD, Sascha Dierks, PhD, Katayoon Shirneshan, PhD, Marc Talló Parra, Roman Martin, PhD, Ulrich Germing, Uwe Platzbecker, MD, Frank Lange, MD, Nicolaus Kroeger, MD, Konstanze Döhner, MD, Bertram Glass, MD, Maike Nickelsen, MD, Reingard Stuhlmann, MD, Lorenz H. Truemper, MD, Julie Schanz, MD, Ulrike Bacher, MD, Detlef Haase, MD

Blood (2016) 128 (22): 2001.

https://doi.org/10.1182/blood.V128.22.2001.2001

Published: 2016

Journal Articles

Landscape of DNA Methylation and Genetic Profiles in 291 Patients with Myelodysplastic Syndromes

Blood (2015) 126 (23): 5205.

https://doi.org/10.1182/blood.V126.23.5205.5205

Published: 2015

Journal Articles

Myelodysplastic Syndromes (MDS) With 20q Deletion Show a High Frequency Of Associated Cytogenetic and Molecular Lesions With An Association To U2AF1 , SRSF2 , and Prognostically Adverse ASXL1 Mutations

Ulrike Bacher, MD, Torsten Haferlach, MD, Susanne Schnittger, PhD, Melanie Zenger, Manja Meggendorfer, PhD, Andreas Roller, PhD, Vera Grossmann, PhD, Maria Theresa Krauth, MD, Sabine Jeromin, PhD, Tamara Alpermann, Alexander Kohlmann, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 657.

https://doi.org/10.1182/blood.V122.21.657.657

Published: 2013

Journal Articles

Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes

Blood (2013) 122 (21): 521.

https://doi.org/10.1182/blood.V122.21.521.521

Published: 2013

Journal Articles

Further Insights Into The Molecular Landscape Of De Novo Acute Myeloid Leukemia (AML) Investigating 1,291 Patients

Torsten Haferlach, MD, Ulrike Bacher, MD, Tamara Alpermann, Wolfgang Kern, MD, Alexander Kohlmann, PhD, Susanne Schnittger, PhD, Claudia Haferlach, MD

Blood (2013) 122 (21): 607.

https://doi.org/10.1182/blood.V122.21.607.607

Published: 2013

Journal Articles

Acute Erythroid Leukemia (AEL) Can Be Separated Into Distinct Prognostic Subsets Based On Cytogenetic and Molecular Genetic Characteristics

Vera Grossmann, MSc, Claudia Haferlach, MD, Susanne Schnittger, PhD, Ulrike Bacher, MD, Franziska Poetzinger, Sandra Weissmann, PhD, Andreas Roller, PhD, Christiane Eder, PhD, Annette Fasan, PhD, Melanie Zenger, Marita Staller, Wolfgang Kern, MD, Alexander Kohlmann, PhD, Torsten Haferlach, MD

Blood (2012) 120 (21): 1394.

https://doi.org/10.1182/blood.V120.21.1394.1394

Published: 2012

Journal Articles

Cyclin D1 ( CCND1 ) mRNA Expression Assessed by Real-Time PCR Is Increased in Patients with Mantle Cell Lymphoma and Contributes to Diagnosis in B-Cell Lymphoma Cases

Ulrike Bacher, MD, Wolfgang Kern, MD, Claudia Haferlach, MD, Tamara Alpermann, Torsten Haferlach, MD, Susanne Schnittger, PhD

Blood (2012) 120 (21): 1595.

https://doi.org/10.1182/blood.V120.21.1595.1595

Published: 2012

Journal Articles

Prognostic Impact of Physiological B-Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post-Transplant Period in Patients with AML

Ulrike Bacher, MD, Maximilian Christopeit, MD, Anneke Heiland, Mascha Binder, MD, Tatjana Zabelina, MD, Francis Ayuk, MD, Christiane Horn, Torsten Haferlach, MD, Carsten Bokemeyer, M.D., Nicolaus Kroeger, MD

Blood (2012) 120 (21): 1406.

https://doi.org/10.1182/blood.V120.21.1406.1406

Published: 2012

Journal Articles

Post-Allogeneic Monitoring with Molecular Markers Detected by Pre-Transplant Next Generation Sequencing (NGS) Predicts Clinical Relapse in Patients with Chronic Myelomonocytic Leukemia (CMML)

Nicolaus Kröger, Thomas Schroeder, MD, Tatjana Zabelina, MD, Anita Badbaran, Ulrike Bacher, MD, Guido Kobbe, MD, Susanne Schnittger, PhD, Alexander Kohlmann, PhD, Torsten Haferlach, MD

Blood (2012) 120 (21): 4212.

https://doi.org/10.1182/blood.V120.21.4212.4212

Published: 2012

Journal Articles

SF3B1 Mutations Are Detectable in 48.9% of Acute Myeloid Leukemia with Normal Karyotype (AML-NK) and ≥15% Ring Sideroblasts and Are Closely Related to FLT3 -ITD and RUNX1 Mutations

Sabine Jeromin, PhD, Ulrike Bacher, MD, Katharina Bayer, Frank Dicker, PhD, Christiane Eder, PhD, Annette Fasan, PhD, Vera Grossmann, MSc, Alexander Kohlmann, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD

Blood (2012) 120 (21): 406.

https://doi.org/10.1182/blood.V120.21.406.406

Published: 2012

Journal Articles

EZH2 Mutations Can Be Detected in 23% of t(10;11)(p13;q14)/ PICALM-MLLT10 Positive Acute Leukemias,

Vera Grossmann, MSc, Ulrike Bacher, MD, Valentina Artusi, MSc, Hans-Ulrich Klein, PhD, Wolfgang Kern, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD, Alexander Kohlmann, PhD, Claudia Haferlach, MD

Blood (2011) 118 (21): 3440.

https://doi.org/10.1182/blood.V118.21.3440.3440

Published: 2011

Journal Articles

Prognosis of MDS Subtypes RARS, RCMD and RCMD-RS Does Not Differ by Cytomorphologic Criteria but Cytogenetics Allows to Delineate a Subgroup with Inferior Clinical Course,

Ulrike Bacher, MD, Wolfgang Kern, MD, Tamara Alpermann, Susanne Schnittger, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2011) 118 (21): 3796.

https://doi.org/10.1182/blood.V118.21.3796.3796

Published: 2011

Journal Articles

Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Nicolaus Kröger, Tatjana Zabelina, MD, Francis Ayuk, MD, Christine Wolschke, MD, Haefaa Alchalby, Anita Badbaran, Djordje Atanackovic, M.D., Georgia Schilling, MD, Orhan Sezer, MD, PhD, Ulrike Bacher, MD, Thomas Stübig, MD, Boris Fehse, Ph.D., Axel R. Zander, MD

Blood (2011) 118 (21): 148.

https://doi.org/10.1182/blood.V118.21.148.148

Published: 2011

Journal Articles

Recovery of KIR Expression After Allogeneic Stem Cell Transplantation in Multiple Myeloma Patients

Thomas Stuebig, Michael Lioznov, Ulrike Fritsche-Friedland, Haefaa Alchalby, MD, Christine Wolschke, Francis Ayuk, Ulrike Bacher, MD, Axel R. Zander, Nikolaus Kroeger, MD

Blood (2011) 118 (21): 4555.

https://doi.org/10.1182/blood.V118.21.4555.4555

Published: 2011

Journal Articles

Multilineage Dysplasia Has No Prognostic Impact in 108 Adult Patients with CEBPA Mutated AML Supporting the WHO Proposal to Classify These Patients As A Molecularely Defined Unique Entity

Torsten Haferlach, MD, Ulrike Bacher, MD, Katja Macijewski, Vera Grossmann, MSc, Alexander Kohlmann, PhD, Tamara Alpermann, Wolfgang Kern, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD

Blood (2011) 118 (21): 1443.

https://doi.org/10.1182/blood.V118.21.1443.1443

Published: 2011

Journal Articles

Patients with Therapy-Related Myeloid Disorders Share Genetic Features but Can Be Separated by Blast Counts and Cytogenetic Risk Groups Into Prognostically Relevant Subgroups,

Ulrike Bacher, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD, Tamara Alpermann, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2011) 118 (21): 3583.

https://doi.org/10.1182/blood.V118.21.3583.3583

Published: 2011

Journal Articles

Deferasirox (Exjade®) Given During Conditioning Regimen (FLAMSA/Busulfan/ATG) Reduces the Appearance of Labile Plasma Iron in Patients Undergoing Allogeneic Stem Cell Transplantation

Annekathrin Fritsch, Claudia Langebrake, PhD, Peter Nielsen, MD, Ulrike Bacher, MD, Michael Baehr, PhD, Dorothee C. Dartsch, PhD, Nicolaus Kroeger, M.D.

Blood (2011) 118 (21): 3023.

https://doi.org/10.1182/blood.V118.21.3023.3023

Published: 2011

Journal Articles

Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients

Nicolaus Kröger, Evgeny Klyuchnikov, MD, Thomas Stübig, MD, Christine Wolschke, MD, Francis Ayuk, MD, Tatjana Zabelina, MD, York Hildebrandt, Ulrike Bacher, MD, Anita Badbaran, Georgia Schilling, MD, Orhan Sezer, MD, PhD, Djordje Atanackovic, M.D., Martin Kropff, MD, Axel R. Zander, MD

Blood (2011) 118 (21): 3024.

https://doi.org/10.1182/blood.V118.21.3024.3024

Published: 2011

Journal Articles

Donor Choice for Allogeneic Stem Cell Transplantation for AML – A Retrospective Single Centre Long-Term Analysis,

Francis Ayuk, MD, Friedericke Bernhardt, MD, Tatjana Zabelina, MD, Thomas Stübig, MD, Haefaa Alchalby, MD, Christine Wolschke, MD, Heinrich Lellek, MD, Ulrike Bacher, MD, Axel R. Zander, MD, Nicolaus Kröger

Blood (2011) 118 (21): 4147.

https://doi.org/10.1182/blood.V118.21.4147.4147

Published: 2011

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens

Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML

Landscape of DNA Methylation and Genetic Profiles in 291 Patients with Myelodysplastic Syndromes

Myelodysplastic Syndromes (MDS) With 20q Deletion Show a High Frequency Of Associated Cytogenetic and Molecular Lesions With An Association To U2AF1 , SRSF2 , and Prognostically Adverse ASXL1 Mutations

Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes

Further Insights Into The Molecular Landscape Of De Novo Acute Myeloid Leukemia (AML) Investigating 1,291 Patients

Acute Erythroid Leukemia (AEL) Can Be Separated Into Distinct Prognostic Subsets Based On Cytogenetic and Molecular Genetic Characteristics

Cyclin D1 ( CCND1 ) mRNA Expression Assessed by Real-Time PCR Is Increased in Patients with Mantle Cell Lymphoma and Contributes to Diagnosis in B-Cell Lymphoma Cases

Prognostic Impact of Physiological B-Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post-Transplant Period in Patients with AML

Post-Allogeneic Monitoring with Molecular Markers Detected by Pre-Transplant Next Generation Sequencing (NGS) Predicts Clinical Relapse in Patients with Chronic Myelomonocytic Leukemia (CMML)

SF3B1 Mutations Are Detectable in 48.9% of Acute Myeloid Leukemia with Normal Karyotype (AML-NK) and ≥15% Ring Sideroblasts and Are Closely Related to FLT3 -ITD and RUNX1 Mutations

EZH2 Mutations Can Be Detected in 23% of t(10;11)(p13;q14)/ PICALM-MLLT10 Positive Acute Leukemias,

Prognosis of MDS Subtypes RARS, RCMD and RCMD-RS Does Not Differ by Cytomorphologic Criteria but Cytogenetics Allows to Delineate a Subgroup with Inferior Clinical Course,

Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Recovery of KIR Expression After Allogeneic Stem Cell Transplantation in Multiple Myeloma Patients

Multilineage Dysplasia Has No Prognostic Impact in 108 Adult Patients with CEBPA Mutated AML Supporting the WHO Proposal to Classify These Patients As A Molecularely Defined Unique Entity

Patients with Therapy-Related Myeloid Disorders Share Genetic Features but Can Be Separated by Blast Counts and Cytogenetic Risk Groups Into Prognostically Relevant Subgroups,

Deferasirox (Exjade®) Given During Conditioning Regimen (FLAMSA/Busulfan/ATG) Reduces the Appearance of Labile Plasma Iron in Patients Undergoing Allogeneic Stem Cell Transplantation

Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients

Donor Choice for Allogeneic Stem Cell Transplantation for AML – A Retrospective Single Centre Long-Term Analysis,

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only